Avoro Capital Advisors LLC Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001633313
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q2 2024 · 41 positions · Total reported value $7.51B · Top-10 concentration 65.3% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 62.1% · 3 new · 15 cut · 0 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q2 2026 → Q3 2026): -15.9% · vs SPY -18.0% · Prev Value $11.14B — last quarter positions weighted by this quarter price moves · ranking
Est. QTD Return (Q3 2026 → newest close): -0.4% · vs SPY -2.6% · Latest Value $9.67B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking
In its Q2 2024 13F filing, Avoro Capital Advisors LLC disclosed 41 equity positions with a combined reported value of $7.51B. The filing implies a focused portfolio: its ten largest positions account for 65.3% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.
The largest disclosed positions as of Q2 2024 were UTHR ($910.70M), MDGL ($575.88M), ASND ($572.34M). By sector, the heaviest allocations are Health Care 74.0%, Other 26.0%. Versus the prior quarter, allocation shifted toward Health Care (+2.6pp) and away from Other (-2.6pp).
Versus the prior quarter, Avoro Capital Advisors LLC opened 3 new positions, trimmed 15 and fully exited 0, a turnover rate of 62.1% of positions. The portfolio's overlap with the prior quarter was 78% of names.
The largest new positions opened in Q2 2024 were BCYC ($14.17M), DYN ($4.08M), NGNE ($801.63K).
Of the 8 positions fully exited versus the prior quarter, the largest were VKTX ($294.38M), ALPN ($228.92M), MGNX ($90.53M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q2 2024)
- BCYC BICYCLE THERAPEUTICS PLC · $14.17M
- DYN DYNE THERAPEUTICS INC · $4.08M
- NGNE NEUROGENE INC · $801.63K
Fully Exited (vs previous quarter)
- VKTX VIKING THERAPEUTICS INC · prev qtr: $294.38M
- ALPN ALPINE IMMUNE SCIENCES INC · prev qtr: $228.92M
- MGNX MACROGENICS INC · prev qtr: $90.53M
- ROIV ROIVANT SCIENCES LTD · prev qtr: $49.02M
- MRNS MARINUS PHARMACEUTICALS INC · prev qtr: $37.43M
- RCKT ROCKET PHARMACEUTICALS INC · prev qtr: $33.97M
- CRSP CRISPR THERAPEUTICS AG · prev qtr: $28.60M
- KYTX KYVERNA THERAPEUTICS INC · prev qtr: $11.80M
Insider Transactions (Form 4)
Latest Avoro Capital Advisors LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
| Transaction date | Activity | Security | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-07-28 | Buy | Scribe Therapeutics, Inc. | 7,905 | $18.25 | SEC filing |
| 2026-07-24 | Buy | Scribe Therapeutics, Inc. | 50,000 | $22.31 | SEC filing |
| 2026-07-24 | Buy | Scribe Therapeutics, Inc. | 2,333,333 | $15.00 | SEC filing |
Fund Profile
Avoro Capital Advisors LLC is an SEC-registered 13F filer based in New York, NY, United States. As of Q2 2026 it reported 26 US equity positions with a combined value of $11.14B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Firm Snapshot
- Headquarters: NEW YORK, NY, United States
- SEC registration: 801-74391 (status: Approved), registered 2012-03-30
- Regulatory AUM (Form ADV): $13.55B as of 2026-03-05
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 2 private funds, of which 1 hedge funds
- Website: avorocapital.com
Portfolio Structure
- 26 positions · $11.14B reported value (Q2 2026)
- Top 10 holdings = 79.5% of reported value
- Largest position: UTHR (UNITED THERAPEUTICS CORP DEL) at 13.5%
- Average position size: $428.32M
Sector Tilt
- Health Care 99.7%
- (classified holdings cover 100% of value)
Quarterly Activity
- Q2 2026: 2 new, 12 added, 3 reduced, 6 exited
- 9 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
2.86M | $910.70M | 12.13% | Hold | |
| 2 |
|
2.06M | $575.88M | 7.67% | Add | |
| 3 |
|
4.20M | $572.34M | 7.62% | Add | |
| 4 |
|
1.24M | $532.59M | 7.09% | Hold | |
| 5 |
|
3.00M | $474.00M | 6.31% | Reduce | |
| 6 |
|
2.43M | $446.80M | 5.95% | Reduce | |
| 7 |
|
11.11M | $426.22M | 5.68% | Hold | |
| 8 |
|
4.56M | $375.21M | 5.00% | Add | |
| 9 |
|
7.54M | $308.29M | 4.11% | Hold | |
| 10 |
|
3.04M | $281.37M | 3.75% | Reduce | |
| 11 |
|
27.40M | $271.81M | 3.62% | Hold | |
| 12 |
|
6.50M | $265.73M | 3.54% | Add | |
| 13 |
|
8.89M | $231.02M | 3.08% | Add | |
| 14 |
|
5.67M | $220.94M | 2.94% | Hold | |
| 15 |
|
3.00M | $205.47M | 2.74% | Add | |
| 16 |
|
4.31M | $155.92M | 2.08% | Reduce | |
| 17 |
|
2.77M | $121.80M | 1.62% | Add | |
| 18 |
|
3.89M | $116.08M | 1.55% | Hold | |
| 19 |
|
400.00K | $97.20M | 1.29% | Add | |
| 20 |
|
11.70M | $93.83M | 1.25% | Hold | |
| 21 |
|
2.09M | $85.34M | 1.14% | Add | |
| 22 |
|
1.35M | $80.18M | 1.07% | Add | |
| 23 |
|
3.89M | $79.83M | 1.06% | Reduce | |
| 24 |
|
12.57M | $77.68M | 1.03% | Reduce | |
| 25 |
|
3.54M | $72.92M | 0.97% | Reduce | |
| 26 |
|
8.06M | $55.13M | 0.73% | Add | |
| 27 |
|
8.76M | $45.72M | 0.61% | Reduce | |
| 28 |
|
575.00K | $43.42M | 0.58% | Hold | |
| 29 |
|
1.84M | $43.24M | 0.58% | Hold | |
| 30 |
|
12.35M | $42.96M | 0.57% | Hold | |
| 31 |
|
18.65M | $41.78M | 0.56% | Hold | |
| 32 |
|
830.00K | $34.11M | 0.45% | Hold | |
| 33 |
|
4.00M | $29.16M | 0.39% | Hold | |
| 34 |
|
2.22M | $28.58M | 0.38% | Hold | |
| 35 |
|
700.00K | $22.10M | 0.29% | Hold | |
| 36 |
|
4.54M | $16.96M | 0.23% | Hold | |
| 37 |
|
700.00K | $14.17M | 0.19% | New | |
| 38 |
|
2.85M | $4.16M | 0.06% | Hold | |
| 39 |
|
115.75K | $4.08M | 0.05% | New | |
| 40 |
|
416.67K | $2.86M | 0.04% | Hold | |
| 41 |
|
22.03K | $801.63K | 0.01% | New | |
FAQ
What did Avoro Capital Advisors LLC buy in 2024-Q2?
In its 2024-Q2 13F filing, Avoro Capital Advisors LLC reported 41 equity positions worth $7.51B in aggregate; its largest disclosed positions were UTHR ($910.70M), MDGL ($575.88M), ASND ($572.34M).
How large is Avoro Capital Advisors LLC's portfolio?
Avoro Capital Advisors LLC reported $7.51B of long equity holdings across 41 positions as of 2024-Q2. Top-10 holdings account for 65.3% of reported value.
What is Avoro Capital Advisors LLC's investment style?
HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.